ENTITY
Sinomab Bioscience Ltd

Sinomab Bioscience Ltd (3681 HK)

12
Analysis
Health CareHong Kong
Sinomab Bioscience Limited manufactures antibody drugs. The Company researches, develops, and manufactures anti-infective drugs, antitumor agents, and monoclonal antibodies. Sinomab Bioscience markets its products worldwide.
more
26 Jul 2022 11:44

Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction

Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...

Logo
317 Views
Share
bullishRemegen
12 Oct 2021 09:04

Remegen Co Ltd (9995.HK) - Insights About the First Round Enquiry by Shanghai Stock Exchange

This article mainly analyzed RemeGen in terms of its reply to Shanghai Stock Exchange’s first round enquiry,  the core products, the pipeline, the...

Logo
254 Views
Share
20 Sep 2021 09:01

China Healthcare Weekly (Sep17) - A New Round of Rebalancing, Artificial Joints VBP, Genetic Testing

The article mainly analyzed the logic of volume-based purchase (VBP) and healthcare sector rebalancing, the results of centralized procurement of...

Logo
264 Views
Share
24 Oct 2020 23:47

What HKEX Biotech "Step-Ups" Can Tell Us

This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...

Share
11 Mar 2020 14:39

InnoCare (诺诚健华) IPO: Momentum Matters but Mind the Limited Upside

InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key...

Logo
420 Views
Share
x